Ribociclib and Abemaciclib: CDK4/6 Inhibitors for the Treatment of Hormone Receptor–Positive Metastatic Breast Cancer

The treatment landscape of hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) metastatic breast cancer has been modernized by the identification of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors. Because the majority of HR+ breast cancers will develop res...

Full description

Saved in:
Bibliographic Details
Published in:J Adv Pract Oncol
Main Author: Byers, Kristina F.
Format: Artigo
Language:Inglês
Published: Harborside Press LLC 2021
Subjects:
Prescriber's Corner
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7844194/
https://ncbi.nlm.nih.gov/pubmed/33552665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6004/jadpro.2021.12.1.8
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items